Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
J Cell Biochem ; 120(4): 6264-6276, 2019 04.
Article in English | MEDLINE | ID: mdl-30378157

ABSTRACT

Though the current therapies are effective at clearing an early stage prostate cancer, they often fail to treat late-stage metastatic disease. We aimed to investigate the molecular mechanisms underlying the anticancer effects of a natural triterpenoid, ganoderic acid DM (GA-DM), on two human prostate cancer cell lines: the androgen-independent prostate carcinoma (PC-3), and androgen-sensitive prostate adenocarcinoma (LNCaP). Cell viability assay showed that GA-DM was relatively more toxic to LNCaP cells than to PC-3 cells (IC50 s ranged 45-55 µM for PC-3, and 20-25 µM for LNCaP), which may have occurred due to differential expression of p53. Hoechst DNA staining confirmed detectable nuclear fragmentation in both cell lines irrespective of the p53 status. GA-DM treatment decreased Bcl-2 proteins while it upregulated apoptotic Bax and autophagic Beclin-1, Atg5, and LC-3 molecules, and caused an induction of both early and late events of apoptotic cell death. Biochemical analyses of GA-DM-treated prostate cancer cells demonstrated that caspase-3 cleavage was notable in GA-DM-treated PC-3 cells. Interestingly, GA-DM treatment altered cell cycle progression in the S phase with a significant growth arrest in the G2 checkpoint and enhanced CD4 + T cell recognition of prostate tumor cells. Mechanistic study of GA-DM-treated prostate cancer cells further demonstrated that calpain activation and endoplasmic reticulum stress contributed to cell death. These findings suggest that GA-DM is a candidate for future drug design for prostate cancer as it activates multiple pathways of cell death and immune recognition.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Autophagy/drug effects , Endoplasmic Reticulum Stress/drug effects , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/immunology , Triterpenes/pharmacology , Calpain/metabolism , Caspase 3/metabolism , Cell Cycle Checkpoints/drug effects , Cell Survival/drug effects , DNA Fragmentation/drug effects , Humans , Male , PC-3 Cells , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Proto-Oncogene Proteins c-bcl-2/metabolism , Signal Transduction/drug effects , Tumor Suppressor Protein p53/metabolism
2.
J Cell Biochem ; 119(2): 2212-2221, 2018 02.
Article in English | MEDLINE | ID: mdl-28857256

ABSTRACT

Melanoma represents an ever-increasing problem in the western world as incidence rates continue to climb. Though manageable during early stages, late stage metastatic disease is highly resistant to current intervention. We have previously shown that gamma-interferon-inducible lysosomal thiol-reductase (GILT) enhances HLA class II antigen processing and immune detection of human melanoma cells. Here we report that GILT expression inhibits a potential target, paired box-3 (PAX-3) protein, in late stage human metastatic melanoma. We also show that GILT transfection or induction by IFN-γ, decreases PAX-3 protein expression while upregulating the expression of Daxx, which is also a repressor of PAX-3. Confocal microscopic analysis demonstrated that GILT co-localizes with PAX-3 protein, but not with Daxx within melanoma cells. Immunoprecipitation and immunoblotting studies suggest that GILT expression negatively regulates PAX-3 through the autophagy pathway, potentially resulting in increased susceptibility to conventional treatment in the form of chemotherapy or radiotherapy. While high-dose radiation is a common treatment for melanoma patients, our data suggest that GILT expression significantly increased the susceptibility of melanoma cells to low-dose radiation therapy via upregulation of tumor suppressor protein p53. Overall, these data suggest that GILT has multiple roles in inducing human melanoma cells as better targets for radiation and immunotherapy.


Subject(s)
Melanoma/metabolism , Oxidoreductases Acting on Sulfur Group Donors/metabolism , PAX3 Transcription Factor/metabolism , Adaptor Proteins, Signal Transducing/metabolism , Autophagy , Cell Line, Tumor , Co-Repressor Proteins , Gene Expression Regulation, Neoplastic , Humans , Lysosomes/metabolism , Melanoma/pathology , Melanoma/radiotherapy , Molecular Chaperones , Neoplasm Staging , Nuclear Proteins/metabolism , Signal Transduction , Tumor Suppressor Protein p53/metabolism
3.
J Cell Biochem ; 116(1): 102-14, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25142864

ABSTRACT

Lymphoma is a potentially life threatening disease. The goal of this study was to investigate the therapeutic potential of a natural triterpenoid, Ganoderic acid A (GA-A) in controlling lymphoma growth both in vitro and in vivo. Here, we show that GA-A treatment induces caspase-dependent apoptotic cell death characterized by a dose-dependent increase in active caspases 9 and 3, up-regulation of pro-apoptotic BIM and BAX proteins, and a subsequent loss of mitochondrial membrane potential with release of cytochrome c. In addition to GA-A's anti-growth activity, we show that lower doses of GA-A enhance HLA class II-mediated antigen (Ag) presentation and CD4+ T cell recognition of lymphoma cells in vitro. The therapeutic relevance of GA-A treatment was also tested in vivo using the EL4 syngeneic mouse model of metastatic lymphoma. GA-A-treatment significantly prolonged survival of EL4 challenged mice and decreased tumor metastasis to the liver, an outcome accompanied by a marked down-regulation of STAT3 phosphorylation, reduction myeloid-derived suppressor cells (MDSCs), and enhancement of cytotoxic CD8+ T cells in the host. Thus, GA-A not only selectively induces apoptosis in lymphoma cells, but also enhances cell-mediated immune responses by attenuating MDSCs, and elevating Ag presentation and T cell recognition. The demonstrated therapeutic benefit indicates that GA-A is a candidate for future drug design for the treatment of lymphoma.


Subject(s)
Lymphoma/drug therapy , Triterpenes/therapeutic use , Animals , Cell Line, Tumor , Cell Survival/drug effects , Humans , Lymphoma/metabolism , Male , Mice , Mice, Inbred C57BL , Triterpenes/pharmacology , Xenograft Model Antitumor Assays
4.
Apoptosis ; 17(10): 1066-78, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22847295

ABSTRACT

Melanoma is the most aggressive form of skin cancer, responsible for the majority of skin cancer related deaths. Thus, the search for natural molecules which can effectively destroy tumors while promoting immune activation is essential for designing novel therapies against metastatic melanoma. Here, we report for the first time that a natural triterpenoid, Ganoderic acid DM (GA-DM), induces an orchestrated autophagic and apoptotic cell death, as well as enhanced immunological responses via increased HLA class II presentation in melanoma cells. Annexin V staining and flow cytometry showed that GA-DM treatment induced apoptosis of melanoma cells, which was supported by a detection of increased Bax proteins, co-localization and elevation of Apaf-1 and cytochrome c, and a subsequent cleavage of caspases 9 and 3. Furthermore, GA-DM treatment initiated a possible cross-talk between autophagy and apoptosis as evidenced by increased levels of Beclin-1 and LC3 proteins, and their timely interplay with apoptotic and/or anti-apoptotic molecules in melanoma cells. Despite GA-DM's moderate cytotoxicity, viable cells expressed high levels of HLA class II proteins with improved antigen presentation and CD4+ T cell recognition. The antitumor efficacy of GA-DM was also investigated in vivo in murine B16 melanoma model, where GA-DM treatment slowed tumor formation with a significant reduction in tumor volume. Taken together, these findings demonstrate the potential of GA-DM as a natural chemo-immunotherapeutic capable of inducing a possible cross-talk between autophagy and apoptosis, as well as improved immune recognition for sustained melanoma tumor clearance.


Subject(s)
Antineoplastic Agents/therapeutic use , Apoptosis/drug effects , Autophagy/drug effects , HLA-D Antigens/immunology , Melanoma/immunology , Melanoma/pathology , Triterpenes/therapeutic use , Animals , Antigen Presentation/drug effects , CD4-Positive T-Lymphocytes/immunology , Humans , Melanoma/drug therapy , Melanoma, Experimental/drug therapy , Melanoma, Experimental/immunology , Mice
5.
Leuk Lymphoma ; 53(2): 305-14, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21854084

ABSTRACT

Malignant B-cells express measurable levels of human leukocyte antigen (HLA) class II proteins, but often escape immune recognition by CD4 + T cells. Resveratrol (Resv) has been the focus of numerous investigations due to its potential chemopreventive and anti-cancer effects, but it has never been tested in the regulation of immune components in B-cell tumors. Here, we show for the first time that Resv treatment enhances HLA class II-mediated immune detection of B-cell lymphomas by altering immune components and class II presentation in tumor cells. Resv treatment induced an up-regulation of both classical and non-classical HLA class II proteins (DR and DM) in B-lymphoma cells. Resv also altered endolysosomal cathepsins (Cat S, B and D) and a thiol reductase (GILT), increasing HLA class II-mediated antigen (Ag) processing in B-cell lymphomas and their subsequent recognition by CD4 + T cells. Mechanistic study demonstrated that Resv treatment activated the recycling class II pathway of Ag presentation through up-regulation of Rab 4B protein expression in B-lymphoma cells. These findings suggest that HLA class II-mediated immune recognition of malignant B-cells can be improved by Resv treatment, thus encouraging its potential use in chemoimmunotherapy of B-cell lymphoma.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , CD4-Positive T-Lymphocytes/immunology , HLA-D Antigens/metabolism , Lymphoma, B-Cell/drug therapy , Lymphoma, B-Cell/immunology , Stilbenes/pharmacology , Antigen Presentation , Blotting, Western , Cathepsins/metabolism , Cell Proliferation , Endocytosis , Flow Cytometry , HLA-D Antigens/immunology , Humans , Lymphoma, B-Cell/metabolism , Resveratrol , Tumor Cells, Cultured
6.
Clin Dev Immunol ; 2011: 780839, 2011.
Article in English | MEDLINE | ID: mdl-22162713

ABSTRACT

While the defects in HLA class I-mediated Ag presentation by Burkitt lymphoma (BL) have been well documented, CD4+ T-cells are also poorly stimulated by HLA class II Ag presentation, and the reasons underlying this defect(s) have not yet been fully resolved. Here, we show that BL cells are deficient in their ability to optimally stimulate CD4+ T cells via the HLA class II pathway. The observed defect was not associated with low levels of BL-expressed costimulatory molecules, as addition of external co-stimulation failed to result in BL-mediated CD4+ T-cell activation. We further demonstrate that BL cells express the components of the class II pathway, and the defect was not caused by faulty Ag/class II interaction, because antigenic peptides bound with measurable affinity to BL-associated class II molecules. Treatment of BL with broystatin-1, a potent modulator of protein kinase C, led to significant improvement of functional class II Ag presentation in BL. The restoration of immune recognition appeared to be linked with an increased expression of a 17 kDa peptidylprolyl-like protein. These results demonstrate the presence of a specific defect in HLA class II-mediated Ag presentation in BL and reveal that treatment with bryostatin-1 could lead to enhanced immunogenicity.


Subject(s)
Antigen Presentation , Antineoplastic Agents/pharmacology , Bryostatins/pharmacology , Burkitt Lymphoma/immunology , CD4-Positive T-Lymphocytes/drug effects , HLA-D Antigens/immunology , CD4-Positive T-Lymphocytes/immunology , Cell Line, Tumor , Humans , Interleukin-2/immunology , Interleukin-2/metabolism , Lymphocyte Activation/immunology , Signal Transduction
7.
J Clin Cell Immunol ; S3: 4, 2011 Dec 11.
Article in English | MEDLINE | ID: mdl-23336088

ABSTRACT

Considering the fact that a key factor in tumor development is the evasion of immune detection, the search for natural products, which have reduced toxicity towards normal tissues as well as immunostimulatory capabilities has received growing interest. One attractive source of antitumor products is the Ganoderma lucidum mushroom, which has been used for centuries as an herbal medicine for the prevention and treatment of a variety of diseases, including cancer, and has been shown to improve immune function. Interestingly, its methanol soluble triterpenoid extracts, namely Ganoderic Acids (GAs), have been the subject of several recent investigations on their chemotherapeutic effects. While current research has revealed GAs' role in inducing apoptosis of cancer cells with a much lower toxicity to healthy cells, little information is available on their in vitro and/or in vivo immune activities. In this review, we aim to discuss the current knowledge on GAs, and their potential as apoptosis inducing as well as immune activating molecules that could be a potential alternative approach for designing novel chemoimmunotherapeutics against malignant diseases. We also discuss other new approaches for exploiting the advantages of using a nanoparticle polymer-GA conjugate as a tool for a sustained and targeted delivery of drug in vivo.

8.
Environ Health Perspect ; 116(7): 930-6, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18629316

ABSTRACT

BACKGROUND: Human exposure to brevetoxins produced by the red tide organism, Karenia brevis, is an increasing public health concern. Using in vitro exposure of rat liver cells to brevetoxin B (PbTx-2), the primary toxin product of K. brevis, we previously showed that it formed C(27,28)-epoxy brevetoxin metabolites capable of covalently binding to nucleic acids, a common initiation step for carcinogenesis. OBJECTIVE: This study was undertaken to evaluate nucleic acid adduction in lung following in vitro and in vivo brevetoxin exposures. METHODS: To clarify reactions of brevetoxin epoxide with DNA, we analyzed reaction products of PbTx-6 (a C(27,28) epoxide metabolite of brevetoxin B) with nucleosides. We also analyzed adducts from nucleic acid hydrolysates of isolated rat lung cells treated with PbTx-2 or PbTx-6 in vitro and lung tissue from rats after intratracheal exposure to PbTx-2 or PbTx-6 at 45 microg toxin/kg body weight. RESULTS: Our results indicate that PbTx-2 forms DNA adducts with cytidine after treatment of isolated lung cells, and forms DNA adducts with adenosine and guanosine after intratracheal exposure. CONCLUSIONS: These results are consistent with metabolic activation of highly reactive brevetoxin intermediates that bind to nucleic acid. These findings provide a basis for monitoring exposure and assessing the hazard associated with depurination of brevetoxin-nucleotide adducts in lung tissue.


Subject(s)
DNA Adducts/metabolism , DNA/metabolism , Dinoflagellida , Lung/drug effects , Marine Toxins/toxicity , Oxocins/toxicity , Animals , DNA Damage , In Vitro Techniques , Lung/cytology , Lung/metabolism , Rats
9.
Toxicol Sci ; 89(1): 57-65, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16221966

ABSTRACT

Brevetoxins are potent marine toxins produced by the dinoflagellate Karenia brevis, the causative organism of Florida red tides. An in vitro metabolism of PbTx-2 was performed using purified cDNA-expressed rat liver cytochrome P-450 (CYP) enzymes and freshly isolated rat hepatocytes. The metabolic activities of six CYP enzymes, CYP1A2, CYP2A2, CYP2C11, CYP2D1, CYP2E1, and CYP3A1, were examined by incubation with PbTx-2 for up to 4 h in the presence of a NADPH-generating system. Further identification of the metabolites produced by CYP1A2 and CYP3A1 was preformed using high performance liquid chromatography-mass spectrometry (LC/MS). Both CYP1A2 and CYP3A1 metabolized PbTx-2 to PbTx-3 (MH+: m/z 897), PbTx-9 (MH+: m/z 899), and a newly recorded diol brevetoxin-2 metabolite (MH+: m/z 929). CYP3A1 also produced a considerably higher amount of BTX-B5 (MH+: m/z 911). Subsequent incubation of PbTx-2 with rat hepatocytes produced additional phase 1 metabolites of MH+: m/z 911, 913, 915, 917, and 931, indicating a CYP-catalyzed epoxidation at H-ring (C27,C28-double bond) and a subsequent A-ring hydrolysis of PbTx-2 metabolic products. A conjugation metabolism was identified by the production of a glutathione-brevetoxin conjugate (MH+: m/z 1222) and a cysteine-brevetoxin conjugate (MH+: m/z 1018). Structures of the new metabolites are postulated, and a likely CYP-catalyzed metabolism pathway of PbTx-2 metabolism are discussed.


Subject(s)
Aryl Hydrocarbon Hydroxylases/metabolism , Dinoflagellida , Hepatocytes/enzymology , Marine Toxins/metabolism , Metabolic Detoxication, Phase II , Animals , Cells, Cultured , Chromatography, High Pressure Liquid , Hepatocytes/drug effects , Male , Marine Toxins/toxicity , Oxidation-Reduction , Oxocins , Rats , Rats, Sprague-Dawley
10.
Toxicon ; 46(3): 243-51, 2005 Sep 01.
Article in English | MEDLINE | ID: mdl-15979117

ABSTRACT

Ciguatera is a human food poisoning caused by consumption of tropical and subtropical fish that have, through their diet, accumulated ciguatoxins in their tissues. This study used laboratory mice to investigate the potential to apply blood collection cards to biomonitor ciguatoxin exposure. Quantitation by the neuroblastoma cytotoxicity assay of Caribbean ciguatoxin (C-CTX-1) spiked into mice blood was made with good precision and recovery. The blood collected from mice exposed to a sublethal dose of Caribbean ciguatoxic extract (0.59 ng/g C-CTX-1 equivalents) was analyzed and found to contain detectable toxin levels at least 12 h post-exposure. Calculated concentration varied from 0.25 ng/ml at 30 min post-exposure to 0.12 ng/ml at 12 h. A dose response mice exposure revealed a linear dose-dependent increase of ciguatoxin activity in mice blood, with more polar ciguatoxin congeners contributing to 89% of the total toxicity. Finally, the toxin measurement in mice blood exposed to toxic extracts from the Indian Ocean or from the Pacific Ocean showed that the blood collection card method could be extended to each of the three known ciguatoxin families (C-CTX, I-CTX and P-CTX). The low matrix effect of extracted dried-blood samples (used at 1:10 or 1:20 dilution) and the high sensitivity of the neuroblastoma assay (limit of detection 0.006 ng/ml C-CTX-1), determined that the blood collection card method is suitable to monitor ciguatoxin at sublethal doses in mice and opens the potential to be a useful procedure for fish screening, environmental risk assessment or clinical diagnosis of ciguatera fish poisoning in humans or marine mammals.


Subject(s)
Ciguatera Poisoning/blood , Ciguatoxins/blood , Environmental Exposure , Animals , Ciguatera Poisoning/epidemiology , Ciguatoxins/toxicity , Dose-Response Relationship, Drug , Gas Chromatography-Mass Spectrometry , Mice , Models, Animal , Neuroblastoma/metabolism , Pacific States/epidemiology , Risk Assessment , Time Factors
11.
Toxicol Sci ; 85(2): 839-46, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15746006

ABSTRACT

We examined detoxification of brevetoxin in rats through metabolic activities and key elimination routes by analyzing samples from individual rats exposed to two brevetoxin congeners (PbTx-2 and PbTx-3). Brevetoxins were detected by radioimmunoassay in methanolic extracts of blood within 1 h post intraperitoneal (ip) administration. The toxin assay response was about three times higher in PbTx-2-treated rats versus the same dose (180 microg/kg) of PbTx-3. This difference persisted for up to 8 h postexposure. When the blood samples were reextracted with 20% methanol to enhance recovery of potential polar brevetoxin metabolites, 25-fold higher assay activity was present in the PbTx-2-treated rats. Analysis of urine from the same animals identified 7-fold more activity in the PbTx-2-treated rats that accumulated over the course of 24 h. Radioimmunoassay-guided high performance liquid chromatographic analysis of urine from PbTx-2-treated rats yielded three major peaks of activity. The first peak was attributed to the two cysteine adducts, cysteine-PbTx sulfoxide and cysteine-PbTx (MH(+): m/z 1034 and 1018). The second peak was attributed to the oxidized form of PbTx-2 (MH(+): m/z 911) and its reduction product PbTx-3. The third peak remains unidentified. Brevetoxin cysteine conjugate and its sulfoxide product contributed nearly three-quarters of the brevetoxin immunoactivity. Our findings indicate the most commonly occurring PbTx-2 is rapidly transformed to a polar metabolite of a reduced biological activity that appears in blood and remains for up to 8 h, yet is cleared mostly to the urine within 24 h.


Subject(s)
Inactivation, Metabolic , Marine Toxins/metabolism , Marine Toxins/toxicity , Oxocins/metabolism , Oxocins/toxicity , Animals , Carbohydrate Sequence , Chromatography, High Pressure Liquid , Cysteine/urine , Indicators and Reagents , Injections, Intraperitoneal , Male , Marine Toxins/chemistry , Mass Spectrometry , Molecular Sequence Data , Oxocins/chemistry , Radioimmunoassay , Rats , Receptors, Drug/metabolism
12.
Toxicon ; 45(1): 107-12, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15581689

ABSTRACT

A separation of toxic components from the upside down jellyfish Cassiopea xamachana (Cx) was carried out to study their cytotoxic effects and examine whether these effects are combined with a binding activity to cell membrane receptors. Nematocysts containing toxins were isolated from the autolysed tentacles, ruptured by sonication, and the crude venom (CxTX) was separated from the pellets by ultracentrifugation. For identifying its bioactive components, CxTX was fractionated by gel filtration chromatography into six fractions (named fraction I-VI). The toxicity of CxTX and fractions was tested on mice; however, the hemolytic activity was tested on saline washed human erythrocytes. The LD50 of CxTX was 0.75 microg/g of mouse body and for fraction III, IV and VI were 0.28, 0.25 and 0.12 microg/g, respectively. Fractions I, II and V were not lethal at doses equivalent to LD50 1 microg/g. The hemolytic and phospholipase A2 (PLA2) activities of most fractions were well correlated with their mice toxicity. However, fraction VI, which contains the low molecular mass protein components (< or =10 kDa), has shown no PLA2 activity but highest toxicity to mice, highest hemolytic activity, and bound significantly to the acetylcholine muscarinic receptors (mAChRs) isolated from rat brain. The results suggested that fraction VI contains proteinaceous components contributing to most of cytolysis as well as membrane binding events. Meanwhile, fraction IV has shown high PLA2 that may contribute to the venom lethality and paralytic effects.


Subject(s)
Cnidarian Venoms/pharmacology , Receptors, Muscarinic/metabolism , Animals , Brain/enzymology , Cnidarian Venoms/isolation & purification , Cnidarian Venoms/metabolism , Male , Mice , Puerto Rico , Rats , Rats, Sprague-Dawley , Scyphozoa/chemistry
13.
Comp Biochem Physiol C Toxicol Pharmacol ; 139(4): 267-72, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15683837

ABSTRACT

Stings of fire corals, potent hydroids common in the Red Sea, are known to cause severe pain and they develop burns and itching that lasts few hours after contact. Nematocyst venom of Millepora platyphylla (Mp-TX) was isolated according to a recent method developed in our laboratory to conduct a previous investigation on the nematocyst toxicity of Millepora dichotoma and M. platyphylla. In this study, Mp-TX was fractionated by using both gel filtration and ion exchange chromatography. Simultaneous biological and biochemical assays were performed to monitor the hemolytic (using washed human red blood cells, RBCs) and phospholipase A2 (using radiolabeled sn-2 C14-arachidonyl phosphatidylcholine as a substrate) active venom fractions. The magnitude of both hemolysis and phospholipase A2 activity was found in a fraction rich of proteins of molecular masses approximately 30,000-34,000 Daltons. The former fraction was purified by ion exchange chromatography, and a major bioactive protein factor (approx. 32,500 Daltons , here named milleporin-1) was recovered. Milleporin-1 enzymatic activity showed a significant contribution to the overall hemolysis of human RBCs. This activity, however, could not be completely inhibited using phospholipid substrates. Melliporin-1 fraction retained about 30% hemolysis, until totally rendered inactive when boiled for 3 min. The overall mechanism of action of milleporin-1 to impact the cellular membrane was discussed; however, it is pending more biochemical and pharmacological future studies.


Subject(s)
Cnidarian Venoms/toxicity , Erythrocytes/drug effects , Hydrozoa/chemistry , Phospholipases A/metabolism , Animals , Cnidarian Venoms/isolation & purification , Erythrocytes/physiology , Hemolysis , Humans , In Vitro Techniques , Phospholipases A/antagonists & inhibitors , Phospholipases A2
14.
Article in English | MEDLINE | ID: mdl-12039682

ABSTRACT

Three common Red Sea soft corals (Cnidaria: Anthozoa), Nephthea sp, Dendronephthya sp and Heteroxenia fuscescens sting humans. Nematocyst venoms of each animal are lethal to mice and hemolytic to human erythrocytes. However, these hemolysins are partially inhibited by known anti-hemolytic agents. Venoms and their gel chromatography-separated fractions have different dermonecrosis and vasopermeability potency in mouse skin. The venom of Heteroxenia fuscescens (Hf) was more lethal (LD50: 0.7 mg/kg), with one prominent 97-kDa protein fraction (LD50: 0.55 mg/kg). Hf venom was more hemolytic, more dermonecrotic, and had more vasopermeable factors than that of the two other species. SDS polyacrylamide gel electrophoresis of soft coral whole venoms and fractions showed different protein molecular masses ranging from 200 to less than 6 kDa. High IgG titers were assayed from venom-sensitized mice blood sera. Enzyme-linked immunosorbent assays (ELISA) marked significant immunological cross-reaction between the studied soft coral venoms and their bioactive fractions.


Subject(s)
Anthozoa/chemistry , Cnidarian Venoms/toxicity , Animals , Anthozoa/cytology , Biological Assay , Chromatography, Gel , Cnidarian Venoms/chemistry , Cnidarian Venoms/immunology , Cnidarian Venoms/isolation & purification , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Erythrocytes/drug effects , Hemolysis/drug effects , Humans , Indian Ocean , Lethal Dose 50 , Male , Mice , Molecular Weight
15.
Comp Biochem Physiol C Toxicol Pharmacol ; 131(3): 323-34, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11912057

ABSTRACT

A method appropriate for isolating of fire coral nematocysts of Millepora dichotoma (Md) and Millepora platyphylla (Mp) was described and compared with techniques that had been used before. Isolated nematocyst venoms of Md (Md-TX) and Mp (Mp-TX) were lethal to mice (had LD50 values of 0.51 and 0.21 microg/g mouse body, respectively) and displayed variable hemolytic, vasopermeable and dermonecrotic properties. The potent hemolysins of Md-TX and Mp-TX, which purified by gel filtration chromatography, possessed prominent proteins of molecular weights 35 and 31 kDa and had LD50 values 0.35 and 0.25 microg/g mouse, respectively. Hemolytic activities of crude venoms and their fraction could be inactivated using known anti-hemolytic agents. Both Md-TX and Mp-TX had distinguishable antigenic properties and their antisera raised in immunized mice and stung human were cross-reactive. ELISA assays showed an antigenic similarity among the studied fire coral homologous cytolytic counterparts.


Subject(s)
Cnidaria/chemistry , Cnidarian Venoms/immunology , Cnidarian Venoms/toxicity , Organelles/chemistry , Animals , Antibodies/blood , Biological Assay , Capillary Permeability/drug effects , Cell Fractionation/methods , Chromatography, Gel , Cnidaria/cytology , Cnidarian Venoms/isolation & purification , Cross Reactions , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Hemolysis/drug effects , Humans , Hydrogen-Ion Concentration , Immunoglobulin G/blood , Indian Ocean , Lethal Dose 50 , Mice , Necrosis , Skin/drug effects , Skin/pathology , Subcellular Fractions/chemistry , Subcellular Fractions/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...